Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort
Por:
Alvarenga, JM, Yeung, JS, Prajapati, V, Ribero, S, Balato, A, Marzano, AV, Cruz, MJ, Lopes, MJP, Lazaridou, E, Carrascosa, JM, Farinha, P, Duarte, B, Sood, S, Rankin, BD, Ortoncelli, M, Caccavale, S, Ferrucci, SM, Rosa, GP, Daponte, AI, Silvi, G, Peris, K, Gori, N, Herranz, P, Prignano, F, Kolios, A, Rompoti, N, Gregoriou, S, Gkalpakiotis, S, Chiricozzi, A and Torres, T
Publicada:
1 feb 2026
Ahead of Print:
1 ene 2026
Resumen:
Introduction. Randomized clinical trials (RCTs) in atopic dermatitis (AD) often exclude older adults and patients with comorbidities, limiting the generalizability of trial findings to real-world populations. Despite the growing use of biologics and Janus kinase inhibitors (JAKis) in clinical practice, the extent to which real-world patients meet RCT eligibility criteria and their associated safety outcomes remains unclear. Methods. We conducted a retrospective analysis of a large, multicenter international cohort of adolescents and adults with AD treated with biologics (dupilumab, tralokinumab) or systemic JAKis (abrocitinib, baricitinib, upadacitinib) between October 2017 and March 2023 across 16 dermatology centers. Eligibility was defined according to commonly applied RCT criteria. Patients meeting >= 1 exclusion criterion were classified as ineligible. Demographic, clinical, and safety outcomes were analyzed. Results. Among 2154 patients, 514 (23.9%) were ineligible. The most frequent reasons were Eczema Area and Severity Index (EASI) < 16 (67.9%), age >= 75 years (21.8%), and cardiovascular disease (13.0%). Ineligibility patterns differed across treatments: patients receiving JAKis were most often ineligible because of EASI < 16 (92.8%), whereas ineligibility among biologic users more commonly reflected also age or cardiovascular comorbidity. Ineligible patients were older, had more non-atopic comorbidities, and had lower measured baseline disease activity.Safety profiles were generally favorable. Among biologic-treated patients, adverse event rates were similar between eligible and ineligible groups. In the JAKi cohort, overall adverse events were more frequent in ineligible patients (52.9% vs. 42.6%; p = 0.051), with acneiform eruption and lipid abnormalities emerging as the most distinct differences. No unexpected safety signals were identified in either treatment group. Conclusion. Nearly one-quarter of real-world patients with AD would not have met eligibility criteria for pivotal RCTs, yet both biologics and JAK inhibitors demonstrated acceptable safety profiles in these populations. While adverse events were more frequent among ineligible patients receiving JAKis, findings require further investigation to determine their clinical relevance, particularly regarding long-term cardiovascular outcomes.
Filiaciones:
Alvarenga, JM:
Unidade Local Saude Santo Antonio Porto, Dept Dermatol, Rua Dom Manuel II 57, P-4050342 Porto, Portugal
Yeung, JS:
Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada
Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada
Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada
Prob Med Res, Toronto, ON, Canada
Prajapati, V:
Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada
Dermatol Res Inst, Calgary, AB, Canada
Skin Hlth & Wellness Ctr, Calgary, AB, Canada
Prob Med Res, Calgary, AB, Canada
Ribero, S:
Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy
Balato, A:
Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy
Marzano, AV:
Fdn IRCCS CaGranda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy
Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
Cruz, MJ:
Unidade Local Saude Sao Joao, Dept Dermatol, Porto, Portugal
Univ Porto, Fac Med, Porto, Portugal
Lopes, MJP:
Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal
Lazaridou, E:
Aristotle Univ Thessaloniki, Sch Med, Dept Dermatol Venereol, Thessaloniki, Greece
:
Hosp Univ Germans Trias i Pujol, Serv Dermatol, Badalona, Barcelona, Spain
Farinha, P:
Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal
Duarte, B:
Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal
Sood, S:
Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
Rankin, BD:
Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada
Ortoncelli, M:
Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy
Caccavale, S:
Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy
Ferrucci, SM:
Fdn IRCCS CaGranda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy
Rosa, GP:
Unidade Local Saude Sao Joao, Dept Dermatol, Porto, Portugal
Univ Porto, Fac Med, Porto, Portugal
Daponte, AI:
Aristotle Univ Thessaloniki, Sch Med, Dept Dermatol Venereol, Thessaloniki, Greece
Silvi, G:
Univ Florence, Dept Hlth Sci, Dermatol Sect, Florence, Italy
Peris, K:
Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy
Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy
Gori, N:
Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy
Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy
Herranz, P:
Hosp La Paz, Dept Dermatol, Madrid, Spain
Prignano, F:
Univ Florence, Dept Hlth Sci, Dermatol Sect, Florence, Italy
Kolios, A:
Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
Rompoti, N:
Natl & Kapodistrian Univ Athens, A Sygros Hospital Skin & Venereal Dis, Fac Med, Dept Dermatol Venereol, Athens, Greece
Gregoriou, S:
Natl & Kapodistrian Univ Athens, A Sygros Hospital Skin & Venereal Dis, Fac Med, Dept Dermatol Venereol, Athens, Greece
Gkalpakiotis, S:
Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Dermatovenereol, Prague, Czech Republic
Charles Univ Prague, Fac Med 3, Prague, Czech Republic
Chiricozzi, A:
Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy
Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy
Torres, T:
Unidade Local Saude Santo Antonio Porto, Dept Dermatol, Rua Dom Manuel II 57, P-4050342 Porto, Portugal
Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal
Green Submitted, gold
|